Literature DB >> 22978350

Response to the comments from Drs Shimazawa and Ikeda.

Rashmi R Shah, Devron R Shah.   

Abstract

Mesh：

Year:  2013        PMID： 22978350      PMCID： PMC3635608          DOI： 10.1111/j.1365-2125.2012.04461.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  2 in total

1.  Evaluation of cytochrome P450-mediated drug-drug interactions based on the strategies recommended by regulatory authorities.

Authors:  Yohei Kosugi; Hideki Hirabayashi; Tomoko Igari; Yasushi Fujioka; Yoko Hara; Teruaki Okuda; Toshiya Moriwaki
Journal:  Xenobiotica       Date:  2011-11-05       Impact factor: 1.908

2.  Are there any differences in the regulations of personalized medicine among the USA, EU and Japan?

Authors:  Rumiko Shimazawa; Masayuki Ikeda
Journal:  Br J Clin Pharmacol       Date:  2013-05       Impact factor: 4.335
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.